ERBB2 and breast cancer: In contrast, lapatinib, another TKI used to treat advanced HER2-positive breast cancer without causing HTN as a side effect, showed an insignificant effect on EC viability and the levels of LEENE, eNOS, and VCAM1 RNA in vitro and ex vivo.